Keywords
Colorectal Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

480 Search results.

Colorectal Cancer Non-Protocol Therapy NCT00303628 - Non-Protocol Therapy Colorectal Cancer NCT00303628 E5204

- 3/25/15 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Header, Non-Protocol Therapy
E5204 Non-Protocol Therapy Form Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer NCT00303628 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=089B4967-A7D1-3905-E044-0003BA3F9857

RO5083945, FOLRIFI and Cetuximab in Colorectal Cancer NCT01326000 - Eligibility Criteria

- 5/14/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01326000 Brief Summary: This randomized, multicenter, open label study will evaluate the safety and efficacy of RO5083945 in combination with FOLFIRI as compared to FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with metastatic colorectal cancer. Patients will be randomized to receive RO5083945 (1400 mg intravenously on Day 1 and Day 8 and every 2 weeks thereafter) plus FOLFIRI standard iv chemotherapy or FOLFIRI plus cetuximab (400 mg/m2 iv on Day 1 followed by 250 mg/m2 iv every week) or FOLFIRI alone. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Eligibility MSI Positive Colorectal Cancer NCT02060188

- 5/12/19 - 1 form, 3 itemgroups, 14 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142); ODM derived from: https://clinicaltrials.gov/show/NCT02060188

Eligibility Metastatic Colorectal Cancer NCT02503150

- 5/11/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02503150

Eligibility Metastatic Colorectal Cancer NCT02448810

- 5/11/19 - 1 form, 2 itemgroups, 45 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02448810

Eligibility Metastatic Colorectal Cancer NCT02404935

- 5/10/19 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients With RAS Wild-type Metastatic Colorectal Cancer); ODM derived from: https://clinicaltrials.gov/show/NCT02404935

Eligibility Metastatic Colorectal Cancer NCT02322736

- 5/10/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR; ODM derived from: https://clinicaltrials.gov/show/NCT02322736

Eligibility Metastatic Colorectal Cancer NCT02300922

- 5/10/19 - 1 form, 1 itemgroup, 24 items, 1 language
Itemgroup: Inclusion Criteria
Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02300922

Eligibility Metastatic Colorectal Cancer NCT02068131

- 5/10/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02068131

Eligibility Metastatic Colorectal Cancer NCT02332499

- 5/9/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703); ODM derived from: https://clinicaltrials.gov/show/NCT02332499

Eligibility Metastatic Colorectal Cancer. NCT02069704

- 5/9/19 - 1 form, 2 itemgroups, 26 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02069704

Eligibility Colorectal Neoplasms NCT02487992

- 3/6/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02487992